LBBW leads €6m series-B for Amcure

Existing investor LBBW led the funding round alongside German government-backed lender KfW, alternative investors MBG Mittelstaendische Beteiligungsgesellschaft Baden-Wuerttemberg and S-Kap Unternehmensbeteiligungs, as well as several private investors.

According to a statement, the company aims to use the capital injection to accelerate clinical development of its cancer treatment, through its Phase-I clinical trial.

Previous funding
In July 2014, the company received a €5m series-A round led by LBBW, alongside KfW, MBG and S-Kap.

Company
Amcure develops a treatment for metastasising solid tumours, called AMC303, which mainly focuses on cancers of the pancreas, head, neck, stomach, colon, breasts and lungs.

The pre-revenues company span out from the Karlsruhe Institute of Technology in 2012 and is headquartered in Eggenstein-Leopoldshafen, near Karlsruhe.

People
LBBW Venture Capital – Harald Poth (senior investment manager).
Amcure – Klaus Dombowsky (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• DACH
• Venture
• Germany